MX2009006891A - Anticuerpos cd44. - Google Patents

Anticuerpos cd44.

Info

Publication number
MX2009006891A
MX2009006891A MX2009006891A MX2009006891A MX2009006891A MX 2009006891 A MX2009006891 A MX 2009006891A MX 2009006891 A MX2009006891 A MX 2009006891A MX 2009006891 A MX2009006891 A MX 2009006891A MX 2009006891 A MX2009006891 A MX 2009006891A
Authority
MX
Mexico
Prior art keywords
antibodies
relates
human
compositions
methods
Prior art date
Application number
MX2009006891A
Other languages
English (en)
Inventor
Haichun Huang
Vahe Bedian
Mohan Srinivasan
Kristopher Toy
Xu Xu
Erika Meaddough
Lan Yang
Advait V Badkar
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2009006891A publication Critical patent/MX2009006891A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención se relaciona con anticuerpos incluyendo anticuerpos humanos y porciones de unión a antígeno de los mismos que se unen a CD44, y que funcionan para inhibir CD44; la invención también se relaciona con inmunoglobulinas de cadena pesada y ligera derivadas de anticuerpos CD44 de humano y moléculas de ácido nucleico que codifican tales inmunoglobulinas; la presente invención también se relaciona con métodos para hacer anticuerpos CD44 de humano, composiciones que comprenden estos anticuerpos y métodos para usar los anticuerpos y composiciones o medicamentos para tratamiento.
MX2009006891A 2006-12-21 2007-12-20 Anticuerpos cd44. MX2009006891A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87610906P 2006-12-21 2006-12-21
PCT/US2007/025975 WO2008079246A2 (en) 2006-12-21 2007-12-20 Cd44 antibodies

Publications (1)

Publication Number Publication Date
MX2009006891A true MX2009006891A (es) 2009-08-28

Family

ID=39563077

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006891A MX2009006891A (es) 2006-12-21 2007-12-20 Anticuerpos cd44.

Country Status (16)

Country Link
US (1) US20100092484A1 (es)
EP (1) EP2102238A4 (es)
JP (1) JP2010512790A (es)
KR (1) KR20090094848A (es)
CN (1) CN101605812A (es)
AR (1) AR064456A1 (es)
AU (1) AU2007338844A1 (es)
BR (1) BRPI0720477A2 (es)
CA (1) CA2672916A1 (es)
CL (1) CL2007003807A1 (es)
MX (1) MX2009006891A (es)
PE (1) PE20081478A1 (es)
RU (1) RU2009128064A (es)
TW (1) TW200846365A (es)
UY (1) UY30776A1 (es)
WO (1) WO2008079246A2 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8231872B2 (en) * 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
EP2403518A4 (en) * 2009-03-06 2013-01-23 Angstrom Pharmaceuticals Inc Compositions and methods for modulating cell migration
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US10232039B2 (en) 2011-04-12 2019-03-19 Duke University Compositions and methods for the treatment of tissue fibrosis
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US20140335084A1 (en) * 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
HUE033704T2 (en) 2012-02-13 2017-12-28 Bristol Myers Squibb Co Enediyne Compounds, its conjugates and uses, and methods for doing so
PT2956173T (pt) 2013-02-14 2017-06-26 Bristol Myers Squibb Co Compostos de tubulisina, métodos de produção e utilização
JP2016510755A (ja) 2013-03-06 2016-04-11 メリマック ファーマシューティカルズ インコーポレーティッド 抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
CN103288958B (zh) * 2013-03-22 2015-03-04 暨南大学 抗癌症干细胞特异性蛋白cd44的单链抗体及其应用
SG11201601047SA (en) 2013-08-14 2016-03-30 Univ Rice William M Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CA2932819A1 (en) 2013-12-09 2015-06-18 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
SG10201913611QA (en) 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
DK3221346T3 (da) 2014-11-21 2020-10-12 Bristol Myers Squibb Co Antistoffer omfattende modificerede konstante områder af tungkæden
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
WO2016115201A1 (en) 2015-01-14 2016-07-21 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
SG11201705636SA (en) 2015-01-26 2017-08-30 Lubris Llc Use of prg4 as an anti-inflammatory agent
MX2017012802A (es) 2015-04-07 2018-04-11 Alector Llc Anticuerpos antisortilina y métodos para su uso.
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
EP3307771A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
SG10201912150TA (en) 2015-10-06 2020-02-27 Alector Llc Anti-trem2 antibodies and methods of use thereof
JP7060502B2 (ja) 2015-10-29 2022-04-26 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
EA201891482A1 (ru) 2015-12-21 2018-12-28 Бристол-Маерс Сквибб Компани Модифицированные антитела для сайт-специфической конъюгации
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
KR20190005924A (ko) 2016-05-10 2019-01-16 브리스톨-마이어스 스큅 컴퍼니 향상된 안정성을 갖는 튜부리신 유사체의 항체-약물 접합체
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
TWI811229B (zh) 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
JP7299160B2 (ja) 2017-08-03 2023-06-27 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
WO2019133512A1 (en) 2017-12-29 2019-07-04 Alector Llc Anti-tmem106b antibodies and methods of use thereof
JP7268038B2 (ja) 2018-01-31 2023-05-02 アレクトル エルエルシー 抗ｍｓ４ａ４ａ抗体及びその使用方法
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
MX2020011828A (es) 2018-05-25 2021-02-09 Alector Llc Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
EA202092747A1 (ru) 2018-05-29 2021-03-16 Бристол-Маерс Сквибб Компани Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления
CN112512638A (zh) 2018-06-08 2021-03-16 艾利妥 抗siglec-7抗体及其使用方法
CA3099176A1 (en) 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
MX2021000009A (es) 2018-07-09 2021-03-09 Five Prime Therapeutics Inc Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
CN111372655A (zh) 2018-07-13 2020-07-03 艾利妥 抗分拣蛋白抗体及其使用方法
WO2020023920A1 (en) 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
TW202016307A (zh) 2018-08-31 2020-05-01 美商阿列克特有限責任公司 抗cd33 抗體及其使用方法
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
FI3886914T3 (fi) 2018-11-30 2023-05-26 Bristol Myers Squibb Co Glutamiinin sisältävän kevytketjun c-terminaalisen jatkeen käsittävä vasta-aine, sen konjugaatteja, ja menetelmiä ja käyttöjä
KR20210102334A (ko) 2018-12-12 2021-08-19 브리스톨-마이어스 스큅 컴퍼니 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
KR102259298B1 (ko) * 2019-05-15 2021-05-31 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
TW202112817A (zh) 2019-06-11 2021-04-01 美商阿列克特有限責任公司 抗揀選蛋白抗體之使用方法
EP4003519A2 (en) 2019-07-31 2022-06-01 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
MX2022006073A (es) 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
KR20220127243A (ko) 2019-12-12 2022-09-19 알렉터 엘엘씨 항-cd33 항체의 사용 방법
US11897968B2 (en) 2019-12-13 2024-02-13 Alector Llc Anti-MerTK antibodies and methods of use thereof
CA3167851A1 (en) 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
JP2023519962A (ja) 2020-03-31 2023-05-15 アレクトル エルエルシー 抗ｍｅｒｔｋ抗体及びその使用方法
CN115667308A (zh) 2020-04-03 2023-01-31 艾利妥 抗trem2抗体的使用方法
WO2021233962A1 (en) 2020-05-19 2021-11-25 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途
WO2022120352A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
JP2024512002A (ja) 2021-03-18 2024-03-18 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
JP2024511610A (ja) 2021-03-23 2024-03-14 アレクトル エルエルシー コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
AU2022278013A1 (en) 2021-05-18 2024-01-18 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
EP4355786A1 (en) 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN116496398B (zh) * 2022-10-31 2023-10-31 南京元迈细胞生物科技有限公司 一种特异性结合CD44的v5外显子的抗体及其用途
CN116554300B (zh) * 2023-04-27 2023-10-24 湖北医药学院 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009811A1 (en) * 1992-10-30 1994-05-11 Duke University An adhesion molecule
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20020055488A1 (en) * 2000-09-21 2002-05-09 Wessels Michael R. Prevention and treatment of streptococcal and staphylococcal infection
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
EP1727564A1 (en) * 2004-03-17 2006-12-06 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury

Also Published As

Publication number Publication date
UY30776A1 (es) 2008-07-03
BRPI0720477A2 (pt) 2014-01-14
RU2009128064A (ru) 2011-01-27
CL2007003807A1 (es) 2008-05-09
CN101605812A (zh) 2009-12-16
JP2010512790A (ja) 2010-04-30
KR20090094848A (ko) 2009-09-08
US20100092484A1 (en) 2010-04-15
EP2102238A2 (en) 2009-09-23
CA2672916A1 (en) 2008-07-03
TW200846365A (en) 2008-12-01
EP2102238A4 (en) 2010-09-01
PE20081478A1 (es) 2008-12-07
AU2007338844A1 (en) 2008-07-03
AR064456A1 (es) 2009-04-01
WO2008079246A3 (en) 2009-01-08
WO2008079246A2 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
MX2009006891A (es) Anticuerpos cd44.
NZ591471A (en) Antibodies to ccr2
PH12014501872A1 (en) P-cadherin antibodies
MX2010007406A (es) Anticuerpos anti-factor inhibidor de migracion de macrofago (mif).
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EA200602210A1 (ru) Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
EP2511301A3 (en) Human antibodies to ERBB2
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
TNSN07394A1 (en) Antibodies to myostatin
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
TW200709817A (en) Platform antibody compositions
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
EA200970874A1 (ru) Антитела против склеростина
WO2008060331A3 (en) Antibodies to sars coronavirus
AU2016219704A1 (en) Anti-Notch1 antibodies
MX2015005719A (es) Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
WO2011004028A3 (en) Tlr3 binding agents
WO2008027739A3 (en) Antibodies to ntb-a
WO2009051957A3 (en) Antibodies to irem-1
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal